- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 3/14 - Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
Patent holdings for IPC class A61P 3/14
Total number of patents in this class: 254
10-year publication summary
|
5
|
2
|
3
|
13
|
13
|
15
|
13
|
15
|
17
|
10
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Epizon Pharma, Inc. | 33 |
14 |
| Daiichi Sankyo Company, Limited | 1875 |
8 |
| Société des Produits Nestlé S.A. | 9329 |
7 |
| Amgen Inc. | 4122 |
7 |
| Wisconsin Alumni Research Foundation | 3885 |
7 |
| LEO Pharma A/S | 431 |
6 |
| Calcilytix Therapeutics, Inc. | 7 |
6 |
| Quincy BioScience, LLC | 49 |
5 |
| Santen Pharmaceutical Co., Ltd. | 601 |
5 |
| Beijing Tuo Jie Biopharmaceutical Co., Ltd. | 31 |
5 |
| Contract Manufacturing Services, LLC | 7 |
4 |
| The Regents of the University of California | 20153 |
3 |
| Abbott Laboratories | 2395 |
3 |
| Alla Chem, LLC | 56 |
3 |
| Amorphical Ltd. | 64 |
3 |
| Delavau LLC | 9 |
3 |
| Glac Biotech Co., Ltd. | 41 |
3 |
| Lupin Limited | 434 |
3 |
| Teijin Pharma Limited | 261 |
3 |
| Bristol-myers Squibb Company | 4840 |
2 |
| Other owners | 154 |